44.28 +0.05 (0.11%)
After hours: 5:57PM EDT
|Bid||44.15 x 1000|
|Ask||44.30 x 1000|
|Day's Range||43.35 - 45.25|
|52 Week Range||18.93 - 59.25|
|Beta (3Y Monthly)||3.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Following a 32-year career with Molson Coors in which he created Blue Moon, brewmaster Keith Villa has launched his own marijuana-infused beer called Ceria.
Marijuana stocks were mixed after New Jersey lawmakers canceled a vote Monday on a bill to legalize recreational cannabis.
Cannabis stocks have gotten a lot of attention on Wall Street in the past year after a handful of popular Canadian growers started hitting the U.S. markets. U.S.-listed names like Canopy Growth Corp (NYSE: CGC), Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) get get most of the publicity.Source: Shutterstock However, OTC-traded stocks Curaleaf Holdings (OTC: CURL), Medmen Enterprises (OTC: MMNFF) and Green Thumb Industries (OTC: GTBIF) could be the best cannabis stocks to invest in. Path To LegalizationIn a new report, Roth Capital Partners analyst Scott Fortune says the cannabis industry has major long-term potential for investors. However, given the massive gains in the most popular stocks in the past year, near-term upside may be limited. Instead, Fortune says the best risk-reward skew in the cannabis space is with U.S. multi-state operators."In our view, the most promising public companies -- i.e., those whose stocks possess the most attractive risk/reward profiles -- are the U.S.-based MSOs -- which are assembling dominant positions in the most lucrative U.S. states," Fortune says.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 3 Things to Watch for Cronos Group Stock Ahead of Earnings Today, these operators are technically violating federal law, which classifies marijuana as a Schedule 1 drug. That classification also keeps these cannabis stocks from listing on the NYSE or Nasdaq exchange. However, Fortune says the STATES Act could be a game-changer for MSOs. The STATES Act wouldn't legalize cannabis on a national level. However, it would exempt companies and individuals from federal enforcement of marijuana laws when inside states with conflicting laws.This legislation would continue the U.S. along the path toward federal legalization and would embolden MSOs to continue to expand their operations. Fortune says once the legalization damn breaks, the financing flood waters will rush in."Federal protection, albeit illegal, has allowed creative risk taking entrepreneurs (MSOs) to quickly gather valuable assets ahead of an eventual large influx of capital investments," he says. Huge Opportunity for Cannabis StocksRoth estimates the $11 billion U.S. cannabis market will more than double in size -- to $23.4 billion -- by 2022. Ultimately, federal legalization will expand that market to at least $59 billion in size, Fortune says.In the long term, Fortune says the social stigma of cannabis will wear off. Eventually, the drug could have a market penetration similar to alcohol today. Roughly half the adult population in the U.S. drinks alcohol. At that penetration rate, the U.S. cannabis market could eventually approach $200 billion. As of early 2019, the top 10 MSOs had a combined market capitalization of around $20 billion. Fortune says that combined market cap could balloon to around $911 billion by 2023. Best Cannabis Stocks to Invest InFortune says the STATES Act will not only help eliminate cannabis marginalization, it will be a huge catalyst for MSOs. Banks located in states where cannabis is legal could be emboldened by the STATES Act and begin to finance cannabis ventures more freely. Investors will certainly see this access to capital as a bullish development. Fortune says MSO valuations could get a big boost as a result.The largest MSO in the U.S. today is Curaleaf, which operates in 12 different states. Curaleaf has a market cap of around $4.6 billion. CURL operates 35 dispensaries, 10 processing operations and 12 cultivation sites.The next largest U.S. cannabis MSO is Green Thumb Industries. Green Thumb operates in 9 states and has 9 manufacturing locations and 61 retail stores. GTBIF's market cap is around $3.1 billion.Finally, the third largest MSO stock is MedMen, which also operates in 12 states. MMNFF has roughly a $1.6 billion market cap. The company has licenses for 76 retail operations and 16 cultivation and processing sites.In addition to the potential for organic growth among MSO cannabis stocks, the industry is consolidating at a rapid pace. Any of these three stocks could be big buyers or even targets for larger companies in the years ahead. * 7 Marijuana Stocks to Play the CBD Trend There's certainly a lot to like about cannabis stocks and the cannabis industry. But investors should be careful about the buying frenzy that has taken place among the most popular names. While U.S.-listed stocks get all the publicity, CURL stock, MMNFF stock and GTBIF stock may be the cannabis stocks with the most upside.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter Compare Brokers The post Analyst's Top 3 Cannabis Stocks Are Not What You Think appeared first on InvestorPlace.
Canopy Growth Corp (NYSE: CGC ) is further strengthening its position as one of the leading cannabis companies in the world by receiving a license to start growing cannabis at its facility in Fredericton, ...
I can't think of a more exciting sector than legal marijuana. But like every industry, a fresh response is necessary following the honeymoon phase. For Cronos Group (NASDAQ:CRON), the company faces a critical earnings report for its fourth quarter. Although CRON stock has gained 70% this year, shares have traded flat since late January.Not only that, the company has incurred heavy volatility heading into fourth-quarter earnings. Further, significant movement in the options market suggests that traders anticipate a big move. Considering that technical momentum has dried up for nearly two months, and that analysts are skeptical of the sector's production capabilities, it's critical that CRON delivers the goods.On paper, the bar is set low. For earnings per share, covering analysts expect CRON stock to "break even" at 0 cents. Estimates range between a loss of a penny to a high of 1 cent. In Q4 2017, Cronos delivered EPS of a penny.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the revenue picture is likely what most investors will focus on. Sales estimates range from $6.5 million to $6.6 million, with consensus averaging $6.5 million. If management hits this target, it would represent over a 300% lift year-over-year. That's an ambitious goal, but reaching it could do a lot of good for Cronos Group stock. * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock Of course, with such a dynamic industry, investors should be prepared for anything. Here are three key considerations for CRON stock ahead of its anticipated Q4 earnings release: Revenue Growth Remains a Strong Point for CRON StockAlthough aiming for a record-breaking $6.5 million sales haul in the upcoming quarter appears aggressive, it's actually quite reasonable. Going back to almost two years ago, Cronos has forwarded bonkers numbers. That's one of the reasons why CRON stock historically is such an outperformer. Click to Enlarge Since Q3 2017, Cronos revenue growth on a YOY basis averages 434%. Taking away this quarter's ridiculous 963% growth, we still have an average of just under 333%. Therefore, a 303% growth target for Q4 2018 is well within established trends.That said, legal marijuana understandably has viability and practicality concerns. If CRON fails to hit its revenue forecast, that could send a ripple effect into Cronos Group stock. Wall Street may perceive such a miss as an underlying sector problem that could also affect rivals like Tilray (NASDAQ:TLRY) and Canopy Growth (NYSE:CGC).Thus, Q4's revenue target presents a tricky situation. Yes, Cronos should reasonably attain this goal based on historical performance. But if it doesn't, the penalty will likely be severe. Inventory Concerns casts Cloud on CRON stockAmong the litany of criticisms against the cannabis industry, a common criticism is capacity. Several players have invested considerable funds acquiring marijuana production facilities. But analysts have voiced concerns that some of these buyouts don't make economic sense. For example, consider the hoopla surrounding Aurora Cannabis' (NYSE:ACB) acquisition of Whistler Medical Marijuana.This goes to show that capacity will always remain a highly-scrutinized metric. After all, a marijuana producer's viability is directly correlated to how much agricultural goods it can produce. However, another important and related figure to watch is inventory.When people talk capacity, they're talking about processed and packaged goods. It doesn't do Cronos Group stock any good if the underlying firm sits on an un-shippable supply glut. Looking at days inventory, though, management must reign this number in.It's not just the fact that the company reported over 748 days inventory in Q3 2018; this metric has risen uncomfortably high in recent quarters. * 5 Stocks To Buy for the Happiest Employees Again, management must trim this trend. If not, I'm not sure if a good narrative can save CRON stock in the nearer-term. What's CRON Doing with their Money?Last year, tobacco giant Altria Group (NYSE:MO) made headlines when it announced a $1.8 billion equity investment in CRON. Naturally, Cronos Group stock launched into orbit after the disclosure.But it wasn't just about the money. Instead, Altria gave Cronos and the entire marijuana industry a credibility boost. If a big company like Altria was willing to stick its neck out, it must recognize the sector's true potential.Specifically for CRON stock, Altria represented money growing on trees. With its massive partner's support, Cronos can embark on its expansionary ambitions.That's the good part. However, stakeholders don't want to listen to bedtime stories indefinitely. At some point, they want results. Inevitably, we have the obvious question: what's Cronos doing with the money?Boosting sales is one thing. However, shareholders also want efficient production, and eventually, a feasible roadmap to consistent profitability.Unfortunately, I'm not entirely convinced that CRON will give analysts what they're seeking in the nearer-term. Therefore, I'd take a cautious approach to Cronos Group stock heading into Q4.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter Compare Brokers The post 3 Things to Watch for Cronos Group Stock Ahead of Earnings appeared first on InvestorPlace.
Choom Holdings (CSE: CHOO) (OTCQB: CHOOF) is planning to expand into Florida, the company announced. Choom subsidiary Choom Holdings USA has signed a letter of intent to acquire a 95% stake in a Florida-based vertically-integrated cannabis applicant. Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) has received a cultivation license from Health Canada for its facility in Fredericton, New Brunswick. Canopy expects that the facility will […]The post Cannabis Stock News Daily Roundup March 25 appeared first on Market Exclusive.
- There are few pure-play public market plays, but one of the hotter IPOs of 2018 was the popular Chinese device-maker Viomi Technology (VIOT). - Over 8 million water heaters are installed each year in the U.S., and with what appears to be a superior product offering, TKLS' 160% growth could just be getting started. Viomi Technology (VIOT) is a China-based maker of internet-connected home appliances, including smart refrigerators, ovens, dishwashers, robot vacuums, speakers and security devices.
Canopy Growth Corporation (NYSE:CGC) has announced that it has signed a contract agreement for the expansion and extension of its previous partnership with cannabis brand company OG DNA Genetics up to 2024. Expanding into the nascent market in Europe Under the new terms of the contract extension, the companies will extend their operations beyond Jamaica […]The post Canopy Growth Agrees on Partnership Extension With OG DNA Genetics appeared first on Market Exclusive.
Canopy Growth Corp. said Monday it has received a licence from Health Canada to grow cannabis at a facility in Fredericton, New Brunswick. The Canadian cannabis company said it expects the facility to produce more than 5,000 kg of cannabis a year with the first harvest expected within six months. The company is expecting to add jobs, including lab supervisors, technologists, growers, post-harvest crews, quality assurance experts, and shipping and maintenance crews. Details of the jobs on offer will be revealed in the coming weeks. Applicants can monitor canopygrowth.com/careers as well as the company's @CanopyGrowth Twitter feed. U.S.-listed shares rose 0.6% premarket and have gained 71% in the last 12 months, while the S&P 500 has gained 8%.
Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (RIV.V) congratulates Canopy Growth Corporation (WEED.TO) (CGC) (“Canopy Growth”) and its portfolio company, Spot Therapeutics Inc. (“Spot”), on receiving a cultivation license from Health Canada for its Fredericton-based production and distribution facility. In 2017, Canopy Growth solidified its expansion strategy in Atlantic Canada when it acquired Spot and made significant local funding commitments in collaboration with Canopy Rivers, ultimately resulting in Canopy Growth being rewarded with one of the first provincial supply contracts in the cannabis industry, pursuant to a landmark MOU with the government of New Brunswick.
SMITHS FALLS , ON and FREDERICTON, NB , March 25, 2019 /CNW/ - Canopy Growth Corporation (TSX: WEED), (NYSE: CGC) ("Canopy Growth" or the "Company") is pleased to announce that it has received a cultivation licence from Health Canada for its facility in Fredericton, New Brunswick . With this licensing, Canopy Growth predicts the facility will initially produce more than 5,000kg of cannabis annually, with first harvests expected to become available to the market within six months. Developed in collaboration with Canopy Rivers Inc. (RIV.V) and operating under Canopy Growth's flagship Tweed brand, the facility will support the Company's global and local operations with high quality, large-scale cannabis production capabilities that will serve the needs of recreational and medical customers.
In an environment that's already seen a great deal of partnering and acquisitions, it's interesting that one of the biggest cannabis producers has gone untouched, and perhaps largely unnoticed. That's Canada's Aphria (NYSE:APHA). Friday's market saw APHA stock close down more than 5%.Don't let the lack of M&A/JV interest deter you from owning Aphria stock. While the premise of teaming up with big-name partners seems like a step forward for cannabis suppliers that need to expand their distribution networks and product lines, in reality, those team-ups may or may not be the game-changers they're hoped to be. Flying solo -- at least for the time being -- may well be the smart move for Aphria here. No Partner YetAlcoholic beverage company Constellation Brands (NYSE:STZ) was the first to get the ball rolling, expanding its small investment in Canopy Growth (NYSE:CGC) to the $4 billion level last August, just ahead of Canada's legalization of recreational marijuana. Altria Group (NYSE:MO) made its own move in December, shelling out $1.8 billion for a 45% stake in Cronos Group (NASDAQ:CRON).InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn both cases the deals were more than mere investments. They were meant to set the stage for collaboration on new products, even without knowing what those products might be or where they may be sold. * 7 Beaten-Up Stocks to Buy as They Reverse Course Thus far, however, Aphria hasn't caught the eye of any legitimate suitors despite the fact that it's the world's third-biggest grower and boasts a licensed distribution network that spans Canada. It's also got rights to sell marijuana in parts of Europe, South America, Africa and Australia, readying it for rapid penetration of the international market when someone wants to make that happen.Source: New Frontier Data'Legitimate' is the operative word here. The much-smaller Green Growth Brands (OTCMKTS:GGBXF) is trying to orchestrate a hostile takeover, but so far few seem interested. Aphria's argument that the offer of 1.57 shares of GGB for every one share of Aphria stock is inadequate has held up.Still, what do Cronos and Canopy Growth have that Aphria doesn't? Not much. But, a lack of a high-profile partner may not entirely matter.Or, maybe Aphria's got an ace in the hole nobody fully realizes it's holding. Remaining PatientContrary to the message that cannabis M&A mania may be sending, the industry's bigger players don't necessarily need booze or cigarette giants to capture market share within the nascent industry.Brand names ranging from Broken Coast, Good Supply, RIFF and Goodfields are all part of the Aphria family, giving the company exposure to all price points and preferences within the recreational marijuana market. It's also entrenched in the cannabis oil and medical marijuana market.But it doesn't yet have a partner.It does want one, though. In November, then-CEO Vic Neufeld acknowledged "We are very desirous, if I could say that. We've had conversations with many entities and beverage is part of it." He went on to explain to BNN Bloomberg "When Aphria makes the ultimate decision to get into bed with a strategic partner, we want to make sure that they bring the brands that we can leverage together with who we are, what our vision is, and our science."Neufeld is now gone, replaced for the time being by interim CEO Irwin Simon. He's of the same mindset though, saying in early January before Neufeld stepped down that suitor Green Growth could become a strategic partner.No executive or insider is terribly stoked about being owned by Green Growth, however. * 10 Stocks on the Rise Heading Into the Second Quarter But, that's not to suggest the company won't find a big-brand partner just because one hasn't come knocking yet. Acting CEO and board chairman Irwin Simon? He's the former chief of food and beverage company Hain Celestial Group (NASDAQ:HAIN). He's got connections within the industry, when the time and opportunity are right. Bottom Line on Aphria StockIn some regards it would be interesting to see a cannabis company shrug off overtures and make a point of developing its own products and distribution channels, free of the influence that a beverage or cigarette outfit may exert.It's not an experiment to make with real capital, though. It's also not an experiment that's likely to take shape. Aphria doesn't have a big investor/partner yet, and Aphria stock has been a sub-par performer since merger-mania began.Holding out for the right deal, however, may actually be a stroke of brilliance rather than a red flag that could benefit APHA stock holders.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post Aphria Doesn't Have A Big Partner Yet, But That's Okay appeared first on InvestorPlace.
It was a big week for cannabis banking, as the SAFE Banking Act, which would provide protection to financial institutions that work with legal, compliant cannabis businesses, was scheduled for its first markup in the House Financial Services Committee Tuesday, March 26. The bill was introduced by Representatives Ed Perlmutter (D-CO), Denny Heck (D-WA), Steve Stivers (R-OH) and Warren Davidson (R-OH) and has 138 co-sponsors in the House. “Allowing banks to work with the cannabis industry is vital for public safety, transparency and increasing access to capital for small businesses and marginalized communities,” said Morgan Fox, spokesman for the National Cannabis Industry Association, which is lobbying heavily for the bill.
Aurora Cannabis (NYSE:ACB) almost appears unstoppable. As a result, ACB stock has achieved highs not seen since before marijuana gained official legal status in Canada. Hemp legalization in the United States and the market's move higher have lifted both Aurora Cannabis and the stock of its peers.Source: Shutterstock However, this move higher has occurred despite Aurora making no moves into the U.S. hemp market. Moreover, ACB stock trades close to levels it saw before it started falling in October, portending a possible double top in the equity.Considering the stock price and other factors, investors should probably avoid Aurora Cannabis stock at these levels.InvestorPlace - Stock Market News, Stock Advice & Trading Tips A Rising Market, U.S. Hemp Has Reignited Cannabis StocksInvestors can find a lot to like about ACB stock. The company reported revenue growth of 387% in its last quarterly report. Moreover, its investments place it on track to become the largest producer in the industry by next year. * 10 Stocks on the Rise Heading Into the Second Quarter This may help explain why ACB stock has more than doubled from the $4.58 per share low the equity reached on Dec. 24. The overall market began a recovery at that time. Still, the U.S. government also signed a farm bill into law that granted legal status to hemp. Thus, Aurora and its peers not only gained access to the U.S. market, but they also benefit from a reignited boom in marijuana stocks.However, this boom is occurring south of the Canadian border in a country with nearly ten times the population. Moreover, reticence about cannabis remains in some parts of the U.S. Interestingly, this may help cannabis stocks as it will delay a potential "sell the news" event comparable to the stock swoon marijuana stocks saw following Canadian legalization.Now trading at just under $10 per share, it is now approaching the $12.52 per share high it achieved right before marijuana achieved full legal status across Canada. The Current ACB Stock Price Should Cause ConcernValuation offers little help when evaluating ACB stock. ACB trades at more than 80 times sales, and full-year profitability will not come until at least next year. However, that comes in lower than its largest peers: Canopy Growth (NYSE:CGC), Tilray (NASDAQ:TLRY) and Cronos Group (NASDAQ:CRON).However, ACB looks cheap only on a comparative basis. Also, high valuations could still influence ACB stock indirectly. So far, the stock has only traded above the $10 per share level for two weeks of its history. As the stock approaches its record high, investors could start to question the valuation. If I were to buy ACB, I would also want to know that the $12.52 level of last October is not a double top.Also, ACB's expansion outside of Canada appears perplexing. The company reported revenues of C$2.9 million ($2.17 million) outside of Canada. It has also expanded into 24 countries across five continents. However, even though it legally can, it has so far chosen not to follow its peers into the U.S. hemp market.Moreover, ACB has relied heavily on stock dilution to fund its expansion. With the company reporting losses and the stock trading at over 80 times sales, I can hardly blame the company for issuing stock to support its expansion. However, it reduces the incentive to pay high multiples. The Bottom Line on Aurora Cannabis StockAmid the recent rally, investors should probably avoid ACB stock at its current levels. Despite my view on ACB stock, Aurora continues to improve its market position. As a result of expansions, it may lead the industry in production by next year. Also, between massive revenue increases and the growth potential of the world cannabis market, one can understand why Aurora Cannabis stock trades at a premium. * 7 Retail Stocks That Will Continue to Rebound in 2019 However, ACB has spent very little of its history trading at or above current levels. To achieve significant growth, traders need to know that the equity is not forming a double top. Moreover, stock dilution has funded much of the company's expansion. This has likely hampered growth in ACB stock. Furthermore, it seems strange that Aurora Cannabis has not followed its peers into the U.S. hemp market. I expect the company to enter the U.S. at some point. Still, the fact that it will lag its peers in such a large market should concern investors.Given the moves to lead its peers in capacity and foreign expansion, I expect Aurora Cannabis to remain one of the more important companies in the industry for a long time to come. However, at current levels, I see more reasons for ACB stock to move down than up.As of this writing, Will Healy did not hold a position in any of the aforementioned securities. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Specialty Retail ETFs to Buy the Industry's Disruption * 5 Stocks To Buy for the Happiest Employees * 3 Out-of-Favor Consumer Stocks to Buy Compare Brokers The post Why You Should Sell Aurora Cannabis Stock Before It Reaches New Highs appeared first on InvestorPlace.
A day after a big rally, stocks were under significant pressure on Friday. This is as Treasury yields threaten to invert and drag banks lower. It also ignites recession fears among investors. Let's look at a few top stock trades to watching going into next week. Top Stock Trades for Tomorrow 1: Bank of AmericaBank stocks are under extreme pressure on Friday. Looking at Bank of America (NYSE:BAC), shares were down 5% at one point during the day. Now off less than 4%, bulls are stepping up to the plate a bit.InvestorPlace - Stock Market News, Stock Advice & Trading TipsStill, this one was breaking out to the upside just the other day. Now we're seeing range support give way. $28 was the floor in this name and now just a few pennies above $27, support has officially gave way.Unless you're a long-term investor, I would avoid BAC stock. At the very least, I'd give it a few days to see how it shakes out. I want to see if $28 will act as resistance or if BAC will fill the gap down to $26.50. It almost filled that gap on Friday, but didn't quite get there.If the gap doesn't hold as support, look for the backside of prior downtrend support to buoy BAC. Top Stock Trades for Tomorrow 2: TiffanyTiffany & Co (NYSE:TIF) shares were jumping on Friday, climbing 3% on a tough day in the markets thanks to better-than-expected earnings. Is it rallying right into resistance though?The stock has been trending higher in a channel for several months and is now breaking out. But the $105 level could be tough to penetrate. For starters, this level was support turned resistance last fall, while potential downtrend resistance is near the area as well. Finally, the 50% retracement for the 52-week range sits just under $106.That said, if TIF can push through this mark, it could trigger a large breakout. If so, see how it handles the 200-day. On a pullback, see if the prior channel resistance holds as support. Top Stock Trades for Tomorrow 3: Papa John'sPapa John's (NASDAQ:PZZA) has added Shaquille O'Neal to its board and as a brand ambassador. This sent the stock higher by almost 6% on Friday. The move propelled PZZA over the 50-week moving average, while the momentum-measuring MACD (green circle) turns more in the bulls' favor.If momentum keeps up, see if PZZA can climb to $55. On a pullback, I want to see the 50-week and 10-week moving averages hold as support. Top Stock Trades for Tomorrow 4: Canopy GrowthOne could make the argument that Canopy Growth (NYSE:CGC) is still consolidating tightly between support and resistance. Loosely speaking, it is. But with Friday's decline below the 20-day and 50-day moving averages and CGC is losing steam.This group -- and this name specifically -- can be volatile. So I'm not saying that it won't snap back on Monday and even breakout higher at some point next week. But at this rate, the name is simply lacking any follow through, meeting sellers each time it nears $48.Even though we've been watching this one for weeks, it may be time for bullish traders to move on after Friday's fall. The close below the 50-day is certainly a negative. Top Stock Trades for Tomorrow 5: NikeDespite beating on earnings and revenue estimates, Nike (NYSE:NKE) stock is falling almost 6% on Friday as guidance disappoints.If the stock doesn't reclaim the 50-day early next week, Nike may have lower to go. If it does reclaim this mark, look for $83 and the 50-day to support the stock. Otherwise, let's see if we can't nab NKE stock on a decline down to the 200-day. That would be a great dip-buying opportunity.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities.Compare Brokers The post 5 Top Stock Trades for Monday: CGC, TIF, NKE, PZZA appeared first on InvestorPlace.
Canopy Growth Corp. (TSX: WEED) (NYSE: CGC) and HollyWeed Manufacturing & Extracts have entered into a multi-year processing agreement. HollyWeed is owned by HollyWeed North Cannabis, the parent company which operates several subsidiaries engaged in the growth, manufacturing, licensing, and production of cannabis and other pharmaceutical grade products. Agreement Extraction Under the terms of the […]The post Canopy Growth to Get Cannabis Resin from HollyWeed Under Extraction Deal appeared first on Market Exclusive.
The ongoing wave of cannabis legalization is good for pot companies, but the trend could be a downer for alcohol stocks, warns DataTrek.